Peptide Library / Detail
Chonluten
Half-life
Approximately 1-2 hours (estimated based on similar short peptides)
Delivery
Subcutaneous or intramuscular injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Chonluten is a short bioregulatory peptide originally developed for respiratory and lung tissue support. It belongs to the class of cytomax peptides designed to modulate cellular activity and gene expression in specific tissues. Research has explored its potential effects on inflammatory pathways and cellular proliferation in various cell types.
Usage
Typical research protocols investigate doses of 10-20 mg administered via subcutaneous or intramuscular injection, typically in cycles of 10-20 days. Some protocols use daily administration while others employ alternate-day dosing. Clinical research has primarily focused on pulmonary applications with treatment cycles repeated at intervals.
Mechanism of Action
Chonluten functions as a bioregulatory peptide that interacts with cellular receptors to modulate gene expression and protein synthesis in target tissues. According to research by Avolio et al. (2022), peptides in this class can regulate proliferative activity and inflammatory pathways in monocyte/macrophage cell lines, potentially influencing cytokine production and cellular differentiation. The peptide appears to work through epigenetic mechanisms affecting tissue-specific cellular repair and homeostasis.
Benefits(6)
- Potential support for respiratory system function and lung tissue health
- Modulation of inflammatory pathways in immune cells
- May support tissue repair and regeneration processes
- Possible regulation of cellular proliferative activity
- Potential improvement in mucosal membrane integrity
- May support healthy immune response modulation
Side Effects(5)
- Injection site reactions (redness, swelling)
- Mild temporary fatigue reported in some cases
- Potential allergic reactions in sensitive individuals
- Limited comprehensive safety data available
- Possible mild headache during initial administration